Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases – author's reply

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|42|1|120-120

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.1, 2015-07, pp. : 120-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 1, 2015-07 ,pp. : 119-120

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 11, 2015-06 ,pp. : 1141-1148

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease—Authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 690-691

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 689-690

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: diverticulosis in inflammatory bowel diseases

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 39, Iss. 8, 2014-04 ,pp. : 899-900

John Wiley & Sons Inc

Access to resources Recommend Favorite